U.S. pharma giant copyright scrapped two experimental weight loss tablets past calendar year—a once-every day pill, lotiglipron, on account of elevated liver enzymes and also a 2 times-daily tablet, danuglipron, on account of solid side effects—but CEO Albert Bourla has stated the company is set to “Perform and win” from the weight problems